Fortis Memorial Research Institute in Gurugram has inaugurated India’s first Centre of Excellence for Myeloma and Lymphoma, a clinical initiative designed to centralize complex blood cancer management. The facility, which launched on June 13, 2026, operates under a specialized model that consolidates diagnostics, cellular therapy, and clinical research into a single integrated platform.
The institution has adopted a clinical philosophy titled One Disease, One Doctor, One Focus to streamline patient care pathways. This approach aims to reduce the fragmentation often associated with treating hematologic malignancies by ensuring that specialists in genomics, pathology, and radiation oncology collaborate directly on individual cases.
Rahul Bhargava, Principal Director and Chief of Hematology, Hemato-Oncology and Bone Marrow Transplant at Fortis Memorial Research Institute, stated that the center serves as a mechanism to translate scientific discoveries into clinical practice. The facility integrates multiple disciplines including CAR-T therapy, data analytics, and translational science to address the biological heterogeneity of blood cancers.
Shrinidhi Nathany, a consultant in molecular hematology and oncology, emphasized the role of genomic profiling in the center’s diagnostic framework. By identifying specific actionable mutations at a molecular level, clinicians can move beyond generalized treatment protocols toward therapies tailored to the genetic profile of a patient’s malignancy.
Yash Rawat, Senior Vice President and SBU Head of Fortis Memorial Research Institute, described the launch as a strategic expansion of the hospital’s hematology capabilities. The institute intends for the center to function as a national referral hub, facilitating both high-acuity patient care and the development of new clinical standards in hematologic oncology.
The center aims to improve clinical outcomes by providing access to advanced stem cell transplantation and cellular therapies that require multidisciplinary oversight. By housing these services within one department, the hospital seeks to minimize the time between diagnosis and the initiation of targeted treatment strategies.
The integration of clinical research into the daily operations of the center suggests a focus on longitudinal data collection and the expansion of clinical trial participation. This research-driven model is intended to contribute to the broader understanding of myeloma and lymphoma progression within the Indian patient population, where the burden of hematologic disease remains a significant public health challenge.
The establishment of this center reflects a broader trend in oncology where institutions are shifting toward disease-specific hubs rather than general hematology departments. This specialization allows for the concentration of technical infrastructure, such as high-throughput genomic sequencing equipment and specialized laboratory support, which are necessary for precision medicine in current clinical practice.
The efficacy of this model will likely be measured by the ability of the center to successfully translate genomic findings into improved survival rates and reduced treatment toxicity for patients. Future success depends on the consistent application of multidisciplinary reviews and the ability to maintain a consistent schedule of clinical trials that address the specific genetic variants prevalent in the region.
The center is expected to serve as a training ground for future hematologists, potentially influencing the standard of care across the region. Observers will monitor how the facility manages the logistical demands of coordinating complex cellular therapies alongside standard oncology treatments, particularly as the demand for advanced cancer care continues to rise across India.
The long-term impact of the initiative remains contingent on the integration of data analytics to refine treatment protocols over time. As the center accumulates patient data, the ability to correlate molecular markers with treatment responses will be a primary indicator of its contribution to hematologic research and the evolution of personalized medicine in the country.
The facility represents a significant investment in the infrastructure required to manage the rising incidence of blood cancers. By focusing on the intersection of molecular biology and patient-centered care, the institute aims to provide a scalable model for other healthcare providers to follow as they seek to improve outcomes for patients with complex hematologic conditions.
